Farooq MS, Jona A, Simons RA, Vargas GM, et al. Adjuvant Immunotherapy for High-Risk Stage II Melanoma: Real-World Utilization and Associated Overall Survival. Ann Surg Oncol 2026 Aug 11. doi: 10.1245/s10434-026-20411.
PMID: 42581280